Yes, resveratrol is metabolized by CYP1B1
Resveratrol undergoes metabolism by the cytochrome P450 enzyme CYP1B1, which converts it to piceatannol, a compound with known anticancer activity. This metabolic pathway has been directly demonstrated in laboratory studies and represents an important mechanism for resveratrol's biological effects 1.
Metabolic Pathways of Resveratrol
Primary CYP Enzymes Involved
Resveratrol is metabolized by multiple cytochrome P450 enzymes, with CYP1B1 playing a confirmed role alongside other isoforms:
- CYP1B1: Catalyzes the aromatic hydroxylation of resveratrol to produce piceatannol (3,5,3',4'-tetrahydroxystilbene), an antileukaemic agent and tyrosine kinase inhibitor 1
- CYP1A2: Plays a major role in human liver metabolism, converting resveratrol to both piceatannol and another tetrahydroxystilbene metabolite (M1) 2
- CYP1A1: Also participates in resveratrol hydroxylation reactions 2
Clinical Significance of CYP1B1 Metabolism
The CYP1B1-mediated conversion is particularly noteworthy because:
- CYP1B1 is overexpressed in a wide variety of human tumors 1
- The metabolite piceatannol has documented anticancer activity 1
- This provides a mechanistic explanation for resveratrol's cancer preventative properties—the parent compound is converted to an active anticancer agent specifically in tumor tissue where CYP1B1 is abundant 1
Modulation of CYP Expression by Resveratrol
Importantly, resveratrol also downregulates CYP1B1 expression in certain contexts. In inflamed human epidermis models, resveratrol treatment reduced CYP1B1 gene expression as part of its anti-inflammatory and barrier-protective effects mediated through aryl hydrocarbon receptor (AHR) pathway modulation 3. Similarly, resveratrol and its methoxy derivatives reduced CYP1B1 mRNA transcript and protein levels by 31-89% in breast epithelial cells 4.
Drug Interaction Considerations
While resveratrol is a substrate of CYP1B1, the primary concern for drug-drug interactions involves CYP3A4 inhibition rather than CYP1B1. Trans-resveratrol significantly inhibits CYP3A4/5 activity in micromolar concentrations through a non-competitive mechanism, presenting potential risks for food-drug interactions with CYP3A4 substrates 5. However, natural resveratrol derivatives do not carry the same interaction risk as the parent compound 5.
Key Caveat
The bidirectional relationship between resveratrol and CYP1B1—where resveratrol is both a substrate and a suppressor of CYP1B1 expression—suggests context-dependent effects that may vary based on tissue type, inflammatory status, and exposure duration.